Table 2.
PD medication of H-Y ≥ 3.0 and H-Y < 3.0 patients.
| Overall | H-Y ≥ 3.0 n=53 |
H-Y < 3.0 n=68 |
P | |
|---|---|---|---|---|
| Levodopa | 121 (100%) | 53 (100%) | 68 (100%) | - |
| Dopamine agonist | 79 (65.29%) | 30 (56.60%) | 49 (72.06%) | 0.08 |
| MAO-B inhibitor | 33 (27.27%) | 16 (30.19%) | 17 (25.00%) | 0.53 |
| COMT inhibitor | 34 (28.10%) | 21 (39.62%) | 13 (19.12%) | 0.01* |
| Amantadine | 48 (39.67%) | 15 (28.30%) | 33 (48.53%) | 0.02* |
| Anticholinergics | 26 (21.49%) | 9 (16.98%) | 17 (25.0%) | 0.29 |
| One PD medication alone (Levodopa alone) |
11 (9.09%) | 7 (13.21%) | 4 (5.88%) | 0.21 |
| Two PD medication | 32 (26.45%) | 14 (26.42%) | 18 (26.47%) | 0.99 |
| Three PD medication | 53 (43.80%) | 22 (41.51%) | 31 (45.59%) | 0.65 |
| Four PD medication | 19 (15.70%) | 7 (13.21%) | 12 (17.65%) | 0.51 |
| Five PD medication | 6 (4.96%) | 3 (5.66%) | 3 (4.41%) | 1.00 |